Skip to content
The Nexus
DossierENTITY

John Carrino

Coverage of John Carrino in the Nexus archive.

Earliest in view: Aug 2 · 20:00 UTCMost recent: Aug 2 · 20:00 UTC
Co-mentioned in this coverage
Weill Cornell Medicineorganization1FDA advisory committeeorganization1RP1 (vusolimogene oderparepvec)topic1
Recent coverage
  • HEALTHAug 2 · 20:00 UTCMEDPAGE TODAY
    'We Should Follow That Signal': What We Heard This Week

    An FDA advisory committee supported RP1 (vusolimogene oderparepvec), a twice-administered treatment, following a statement by John Carrino of Weill Cornell Medicine emphasizing the importance of following observed signals in the data.

John Carrino · Dossier · The Nexus